Contrasting Edesa Biotech (NASDAQ:EDSA) and Prothena (NASDAQ:PRTA)

Edesa Biotech (NASDAQ:EDSA) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Insider and Institutional Ownership

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 22.6% of Edesa Biotech shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Edesa Biotech has a beta of -0.68, suggesting that its stock price is 168% less volatile than the S&P 500. Comparatively, Prothena has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Edesa Biotech and Prothena, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1	0	1	0	2.00
Prothena	2	4	4	1	2.36

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential downside of 9.42%. Prothena has a consensus price target of $21.67, indicating a potential upside of 106.35%. Given Prothena’s stronger consensus rating and higher possible upside, analysts plainly believe Prothena is more favorable than Edesa Biotech.

Profitability

This table compares Edesa Biotech and Prothena’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-163.57%	-52.54%
Prothena	-2,520.57%	-65.89%	-56.00%

Earnings & Valuation

This table compares Edesa Biotech and Prothena”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19 million	($1.15)	-4.80
Prothena	$9.68 million	58.39	-$244.09 million	($4.54)	-2.31

Edesa Biotech has higher earnings, but lower revenue than Prothena. Edesa Biotech is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Summary

Prothena beats Edesa Biotech on 9 of the 14 factors compared between the two stocks.

About Edesa Biotech

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.